Intellia Therapeutics, Inc.
Nasdaq · Healthcare · In Vitro & In Vivo Diagnostic Substances · Cambridge, MA
NTLA chart
What traders are saying about $NTLA
Latest postsIntellia Therapeutics, Inc. news
- Hereditary Angioedema Market Size Expected to Climb Sharply
openPR.com ·
- Biogen Inc. (BIIB) stock price, news, quote and history
Yahoo Finance UK ·
- Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA?
StockInvest.us ·
- Intellia Therapeutics, Inc. Estimates – NASDAQ:NTLA
TradingView ·
- Learn Why The Bull Case For Intellia Therapeutics Stock Could Change Following New CMO Appointment
Simply Wall Street ·
- The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Yahoo Finance ·
- 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Yahoo Finance ·
- Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance
Yahoo Finance ·
- Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
Yahoo Finance ·
- Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Yahoo Finance ·
- Why Cathie Wood Is Taking Profits on AMD Stock
barchart.com ·
- Nike downgraded, Home Depot initiated: Wall Street's top analyst calls
Yahoo Finance ·
Intellia Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M |
| Diluted EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 |
| Total assets (year end) | $842.1M | $1.19B | $1.30B | $1.52B |
| Cash and equivalents (year end) | $155.5M | $189.2M | $226.7M | $523.5M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Intellia Therapeutics, Inc.
- Ticker
- NTLA (Nasdaq)
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1652130
Frequently asked questions
What exchange is Intellia Therapeutics, Inc. listed on?
Intellia Therapeutics, Inc. trades on the Nasdaq under the ticker symbol NTLA.
What industry is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. is classified by the SEC under "In Vitro & In Vivo Diagnostic Substances", part of the Healthcare sector on StockTweeting.
Where is Intellia Therapeutics, Inc. headquartered?
Intellia Therapeutics, Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Intellia Therapeutics, Inc.'s fiscal year end?
Intellia Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Intellia Therapeutics, Inc. report?
Intellia Therapeutics, Inc. reported $67.7M in revenue for calendar year 2025, according to its SEC filings.